Frisio Dario G, Ventura Vera
Department of Environmental Science and Policy, Università degli Studi di Milano, 20133 Milano, Italy.
Department of Civil, Environmental, Architectural Engineering and Mathematics, University of Brescia, 25133 Brescia, Italy.
Plants (Basel). 2021 Nov 23;10(12):2558. doi: 10.3390/plants10122558.
The use of plants as biofactories for the production of medical products and vaccines has a long history, but the recent COVID-19 pandemic has caused this set of technologies, for their potential to contribute to the development of innovative solutions for tackling pandemic spread worldwide, to rise in prominence. The purpose of this paper is to analyze the global innovation scenario of plant-based vaccine production.
Patent search using a specific set of technical classification codes and keywords was performed using the Questel-Orbit database, with a final output of 180 patent families, corresponding to 1397 single patents.
Plant-based vaccines production is an innovation sector with positive development especially in the last five-year period (30% growth). Fifty percent of the patents were registered in the United States, standing out as the most attractive patent system worldwide. The inventive activity was led by private firms owning the 49% of the patent families, and the key-players group includes the companies that successfully developed plant-based COVID-19 vaccine candidates, indicating a strong connection between the expertise in innovation production and the capacity to adapt inventions to the current pandemic vaccine demand. Virus-like particles technology has increased in importance over the past few years.
Patent data confirm their relevant role as indicators of innovation and technological evolution. Plant-based vaccines are expected to acquire an increasing role over the next few years as the current pandemic acts as an innovation catalyst.
利用植物作为生产医疗产品和疫苗的生物工厂有着悠久的历史,但近期的新冠疫情使这一系列技术因其在为应对全球疫情传播开发创新解决方案方面的潜力而备受瞩目。本文旨在分析基于植物的疫苗生产的全球创新情况。
使用Questel-Orbit数据库,通过一组特定的技术分类代码和关键词进行专利检索,最终输出180个专利家族,对应1397项单项专利。
基于植物的疫苗生产是一个创新领域,发展态势良好,尤其是在过去五年(增长30%)。50%的专利在美国注册,美国是全球最具吸引力的专利体系。发明活动由拥有49%专利家族的私营公司主导,关键参与者群体包括成功开发出基于植物的新冠疫苗候选产品的公司,这表明创新生产专业知识与将发明应用于当前大流行疫苗需求的能力之间存在紧密联系。在过去几年中,病毒样颗粒技术的重要性不断提高。
专利数据证实了它们作为创新和技术发展指标的相关作用。随着当前疫情成为创新催化剂,预计基于植物的疫苗在未来几年将发挥越来越重要的作用。